

TOGETHER, LET'S

SPARK HOPE

STRENGTHENING OUR **P**RACTICE WITH **A**PPROACHES,
RESOURCES AND **K**NOWLEDGE THAT **H**ELP
OPTIMIZE **P**ATIENT **E**XPERIENCE

JULY 7 - 10, 2021
6:30-9:00 PM / ONLINE



PHILIPPINE SOCIETY OF MEDICAL ONCOLOGY
19TH MIDYEAR CONVENTION

Message

Spark hope!

To spark is to ignite, to kindle, to excite, or to inspire.
This act stirs a lot of energy within us.
It can set in motion something that's been dormant.
It triggers something static.
It inspires when everything is dull and ordinary.

Hope is the power that propels us forward when everything seems lost and uncertain.
Hope is that energy, however faint that we hold on to when there's nothing else to cling to.
Hope is one of a cancer patient's greatest allies.
Hope can be a powerful tool of empowerment.
Hope sustains life and the will to live.

We hope for better times.
We hope for remission.
We hope for a cure.
We hope to prolong life by averting death through medical treatment.
We hope to improve the quality of life through supportive care.
Or, if the disease progresses, we hope to control pain and relieve suffering.

Our midyear convention aspires to spark hope in everyone, although we know that it has always been there, deep within an oncologist's heart.
Hope propelled us through med school, residency and fellowship.
Hope pushed us to adapt to the changes brought about by the pandemic.
It gave us strength as we continued taking care of our patients amidst the fear and uncertainty of the situation.

As we continue what we have started, as we remain true to our commitment, please allow this midyear gathering, meant not just to educate but also to renew our bonds and arouse camaraderie to spark hope and bring joy and love.

Welcome to our midyear convention!

Mabuhay ang PSMO!



A handwritten signature in black ink, which appears to read "Buenaventura C. Ramos, Jr.".

BUENAVENTURA C. RAMOS, JR, MD, FPCP, FPSMO
President

Message

Over a year has passed since the start of this pandemic — and, with each day, the weight that it poses on all of us grows more palpable. Our theme reflects our commitment: “Spark Hope: Strengthening our Practice with Approaches, Resources, and Knowledge that Help Optimize Patient Experience.” As a medical community, by continuing to learn and educate during tumultuous times, we are already showing that life can still go on, and that COVID is not enough to permanently break our spirits. As doctors, our mission is to extend the compassionate touch of the Divine Physician, with our patients and their experiences at the center.



It is also hope that drives our Society to proactively adapt and innovate amidst the challenges. We have developed our own PSMO microsite to cater to our members' needs, and this convention marks the first time we are using it.

Our midyear conventions have always served both as a venue for medical oncologists from across the country to share valuable insights on cancer research and as an opportunity for us, colleagues, to reconnect through teambuilding activities. We are grateful for this chance to come together, albeit virtually, through the support of well-founded organizing committee members, partners, and stakeholders, and through everyone's presence.

We warmly welcome you to the 19th Midyear Convention of the Philippine Society of Medical Oncology! Together and, for the Filipino people, let us all continue joining hands to spark hope.

A handwritten signature in black ink, appearing to read "J. Contreras-Tolentino".

JOSEPHINE P. CONTRERAS-TOLENTINO, MD, FPCP, FPSMO
Overall Chair, 19th Midyear Convention

Message

Good day, to PSMO Officers and Board Members, to the PSMO past presidents, Institutional Chairs and Training Officers, mentors, colleagues and friends

It's a great pleasure to be with you all!

When the scientific committee was beginning to conceptualize the theme for this year's convention, we had YOU in our minds— (1) the dutiful physician who braves the hospital scene despite the pandemic uncertainties to help the patients in need; (2) the worrying mom and dad who constantly prays for our health and for our safe return to home while the kids wonder why you need to stay away and cannot play with them right away; (3) the hospital leaders and authorities figuring out how to effectively keep each other safe from danger; (4) to the victims of Covid19 who steadfastly puts their faith in God for healing; (5) the family or friend who listens and consoles the other tirelessly despite inner struggles. This gathering is for YOU! This gathering is to CELEBRATE YOU, God's gift! We welcome YOU, COURAGEOUS AND BEAUTIFUL SOULS for it is your SPARK that brightens the world. It is YOUR LIGHT that brings HOPE, calms the heart of the anxious and YOU bring inspiration to many! You may not hear it everyday, but you are honored, loved, appreciated and respected for being you.

With God's grace, let us together heal and ignite our SPARKS for a better tomorrow! To our brave heroes, may your LIGHT SHINE and continue to be a blessing.

Welcome to the 19th Midyear Convention!



A handwritten signature in black ink, appearing to read 'Herdee'.

HERDEE GLORIANE C. LUNA, MD, FPCP, FPSMO
Chair, Scientific Committee
19th Midyear Convention

Scientific Program

WEDNESDAY - JULY 7, 2021

06:20 - 06:50PM

OPENING CEREMONIES

OPENING PRAYER by

WELCOME ADDRESS

Herdee Gloriane C. Luna, MD - Scientific Committee Chair

OPENING REMARKS

Josephine P. Contreras-Tolentino, MD - Overall Chair

PSMO PRESIDENT'S MESSAGE AND

OPENING OF THE MIDYEAR CONVENTION

Buenaventura C. Ramos, Jr., MD

SESSION I

06:50 - 07:20PM

Spark Hope: Blessed, Broken and Given Away

Keynote Speaker: BRO. BO SANCHEZ

07:20 - 07:30PM

Video Presentation

SESSION II

07:30 - 08:05PM

Role of Lenvatinib in the management of HCC: The Present and Future

Speaker: CHOO SU PIN, MD

Sponsor: HI-Eisai Pharmaceutical

How to use Eribulin in clinics: Maximizing Survival Outcome

Speaker: SEE HUI TI, MD

Sponsor: HI-Eisai Pharmaceutical

08:05 - 08:15PM

LIVE Q AND A

Moderator: NECY S. JUAT, MD

08:15 - 08:30PM

BREATHHER SESSION 1

Understanding our furry Babies

08:30PM

RAFFLE

THURSDAY - JULY 8, 2021

08:00AM - 05:00PM **VISIT TO VIRTUAL BOOTHS**

SESSION III

06:30 - 07:00PM

Role of Biosimilars in Value-based Medicine in Oncology: Experience with Biosimilar Trastuzumab

Speaker: PROF. DR. CORNELIUS F. WALLER

Sponsor: Viatris Philippines

07:00 - 07:15PM

LIVE Q AND A

07:15 - 07:30PM

BREATHHER SESSION 2

There is no better camera than your phone camera

SESSION IV

07:30 - 08:00PM

Improving Outcomes of EGFR Mutated Non-Small Cell Lung Cancer Beyond FLAURA

Speaker: GERARDO H. CORNELIO, MD

Sponsor: Astra Zeneca

08:00 - 08:15PM

LIVE Q AND A

Moderator: GUIA ELENA IMELDA R. LADRERA, MD

08:15 - 08:45PM

INDUCTION OF NEW ASSOCIATE MEMBERS

inducting Officers: ALLEN S. EVARISTO, MD
Chair, PSMO Membership Committee

BUENAVENTURA C. RAMOS, JR., MD
PSMO President

08:45PM

RAFFLE

FRIDAY - JULY 9, 2021

08:00AM - 05:00PM **VISIT TO VIRTUAL BOOTHS**

SESSION V

06:30 - 07:00PM

The Role of Biosimilar Filgrastim in Chemotherapy Induced Neutropenia

Speaker: SREEDHAR SAGI, MD

Sponsor: Sandoz, Philippines

07:00 - 07:15PM

LIVE Q AND A

07:15 - 07:30PM

BREATHHER SESSION 3

How To Give the Right TLC for our Plants

SESSION VI

07:30 - 08:00PM

Help Keep What Matters Intact. Preventing Bone Complication through Denosumab

Speaker: ANNIELYN BERYL A. ONG-CORNEL, MD

Sponsor: Amgen Philippines

08:00 - 08:15PM

LIVE Q AND A

08:15 - 08:20PM

RAFFLE

SATURDAY - JULY 10, 2021

08:00AM - 12:00NN

VISIT TO VIRTUAL BOOTHS

02:00 - 04:00PM

PSMO BUSINESS MEETING

SESSION VII

06:30 - 07:00PM

Raising Standards in HR+/HER2-mBC with CDK4/6 Inhibitors Measuring Recent Progress

Speakers:

- SHAHEENA DAWOOD, MD
- ELLIE MAY B. VILLEGAS, MD

Sponsor: Pfizer, Inc.

07:00 - 07:15PM

LIVE Q AND A

07:15 - 07:20PM

RAFFLE

07:20PM

PSMO FELLOWSHIP NIGHT

Curriculum Vitae



BRO. BO SANCHEZ

Bo Sanchez is a bestselling author of more than 60 books. He is the founder of ministries that help the poorest of the poor, such as Anawim, a special home for the abandoned elderly, and Grace to be Born, a center for pregnant women in crisis. Bo started a media ministry, a counseling ministry, and a community called Light of Jesus Family that's found in 36 countries.

Privately, Bo also started the TrulyRichClub that has helped thousands learn financial stewardship, and Catholic Filipino Academy Homeschooling to help parents teach their kids at home.

Bo is also an entrepreneur to support his family; In this way, for many years now, he has refused to be paid a salary from his ministries. He also donates his book royalties to the mission.

Above all these, Bo believes that his first call from God is to be a loving husband to his wife Marowe and a devoted father to his sons Benedict and Francis. They live in Manila, Philippines.

Follow him at:

[Facebook.com/BrotherBoSanchez](https://www.facebook.com/BrotherBoSanchez)

[Instagram.com/BrotherBoSanchez](https://www.instagram.com/BrotherBoSanchez)

www.BoSanchez.ph.



CHOO SU PIN, MD, BMedSci, BMBS(Nottm), MRCP(UK), FAMS (Medical Oncology)

Dr. Choo Su Pin is a medical oncologist who specializes in gastrointestinal cancers including colorectal, upper gastrointestinal, pancreas, hepatobiliary, peritoneal, anal and neuroendocrine cancers.

Has a strong experience in running clinical trials in gastrointestinal oncology, including dealing with complex and novel therapeutics and had publications in high impact journals like Lancet, Nature Genetics, Journal of Clinical Oncology, Annals of Oncology and Cancer Discovery.

A graduate from University of Nottingham Medical School, UK. She has fellowships from the Royal College of Physicians, UK and the Academy Of Medicine, Singapore and was trained in medical oncology at the National Cancer Centre Singapore (NCCS).

She holds the positions of Adjunct Associate Professor, Singhealth Duke-NUS Oncology Academic Clinic Programme, Duke-NUS Graduate Medical School Singapore and was Adjunct Associate Professor, Department of Medicine, Yong Loo Lin Medical School, National University of Singapore where she has done both research mentorship and clinical teaching.

Curriculum Vitae



SEE HUI TI, MD

Dr See Hui Ti is a Senior Consultant, Medical Oncologist at Parkway Cancer Centre in Singapore.

She specializes in Breast and Gynecologic cancers where most of her research publications and literary contributions are focused.

Worked at the Queen Elizabeth Hospital in Birmingham, UK, before continuing her internal medicine training at the Singapore General

Hospital.

Awarded by the Singapore Government the Health Manpower Development Plan (HMDP) fellowship after completing advanced oncology training at the National Cancer Centre. She furthered her training in Medical Oncology at the M.D. Anderson Cancer Center in Houston, Texas and obtained her fellowship from the college of physicians (FRCP) from Edinburgh.

A member of the International Gynecologic Cancer Society, American Society of Clinic Oncology and the Singapore Medical Association.



PROF. DR. CORNELIUS WALLER

Dr. Cornelius Waller did his medical training at the University of Tuebingen, Germany, St. Bartholomew's Hospital, London, and the Universitätsspital Zurich, Switzerland from 1983 – 1990. In 1990 he got his license as Medical Doctor and completed his doctoral thesis on "In Vivo validation of image-directed Doppler measurements of superior mesenteric artery blood flow.

Between 1990-2000 he completed his medical residencies at the University Hospital of Freiburg, Germany. This was interrupted by two postdoctoral fellowships at the Department of Molecular Biology at Princeton University, Princeton, USA (1992-1994) and at the Department of Cancer Biology at the Cleveland Clinic Foundation, Cleveland, USA (1994). In November 1994 Cornelius Waller continued his residency at the Department of Haematology and Oncology at the University Medical Center Freiburg, Germany.

He has board certifications for Internal Medicine (2000), Haematology and General Oncology (2001), respectively, and Palliative Care (2007).

Curriculum Vitae

In 2000, he completed his "Habilitation" on "Mobilization and purging of autologous hematopoietic stem cells for transplantation after high-dose chemotherapy in malignant disease" and was awarded the Academic Teaching License by the University of Freiburg, Germany. He was promoted to Associate Professor in 2006.

Since 2007 Dr. Waller is an attending physician and responsible coordinator of the Freiburg University Lung Cancer Center, also he is Attending Physician for the urogenital cancer center and at the Department of Haematology, Oncology and Stem Cell Transplantation.

He has been an Investigator, co-investigator and principal investigator in numerous clinical trials with a special focus on lung and breast cancer, testicular cancer, supportive care and biosimilar development since 1994.

He is member of the German Cancer Society, the German Society of Haematology and Oncology, the European Society for Medical Oncology (ESMO), the American Society of Clinical Oncology (ASCO) and the German Society of Internal Medicine.



GERARDO H. CORNELIO, MD

Dr. Cornelio is a Diplomate and Fellow of the Philippine College of Physicians and Philippine Society of Medical Oncology. He obtained his Doctor of Medicine degree at Dela Salle University Medical Center, Cavite, Philippines.

He had his residency training in Internal Medicine at the University of the Philippines- Philippine General Hospital and was awarded the Most Outstanding Resident in Internal Medicine. He had his post- residency Fellowship in Medical Oncology in the same institution and held the post of Chief Fellow. He then took a post- graduate Clinical Fellowship at the National Cancer Center, Singapore General Hospital.

He is a Clinical Associate Professor of Medicine of the University of the Philippines- Manila and is a past Chairman of the Department of Medicine of San Juan de Dios Hospital, Pasay City. He is the present Director of the Cancer Institute of St. Luke's Medical Center Global City, Taguig City. He is also a past president of the Philippine Society of Medical Oncology.

He is a prolific researcher and was awarded the Most Outstanding Researcher in 2008 by the Philippine Society of Oncologists. He is an author and co- author of numerous clinical trials in breast cancer, lung cancer, prostate cancer and colorectal cancer.

Curriculum Vitae



SREEDHAR SAGI, MD

Dr. Sreedhar Sagi is the Head of Sandoz International Region (Asia-Pacific, Middle East, Africa, Latin America) , a Novartis company. He oversees all Medical Affairs activities and is responsible for the Medical Affairs strategy and its implementation in the Sandoz International Region.

Prior to his current role, he was Head of Safety Risk Management at Sandoz Global Headquarters in Germany, with responsibility for all Sandoz products worldwide, for Risk Management Plans and for Medical Risk Assessments for product quality issues.

In a previous role, he was managing the Safety of Biosimilars, where he was responsible for the set-up, optimization and implementation of Safety Risk Management processes for Biosimilars at a global and national level. He has been with Sandoz/ Novartis since May 2007.

He holds Master's Degrees in Pharmacy (Andhra University, India) and Master's Degree in Biotechnology (Hochschule Mannheim, Germany), and a Ph.D in Medical Biotechnology from Heidelberg University in Germany.



ANNIELYN BERYL A. ONG-CORNEL, MD, FPCP, FPSMO

Dr. Cornel is Diplomate and Fellow of the Philippine College of Physicians and Philippine Society of Medical Oncology. She is a graduate of the College of Medicine of the University of the East Ramon Magsaysay Memorial Medical Center.

She had her residency training in Internal Medicine and post-residency fellowship in Medical Oncology at the Veterans' Memorial Medical Center, Quezon City, Philippines. She then became a research fellow in Medical Oncology in the same institution and went on a Clinical Preceptorship at The Royal North Shore Hospital in Sydney, Australia 2006.

She holds numerous teaching posts both in Academics and specialty training programs. She is an Associate Professor of the Dept. of Medicine at the Jonelta Foundation School of Medicine, University of Perpetual Help DALTA Medical Center Las Pinas, Philippines where she also held the post of Associate Chair for Academics. She is the Assistant Section Chief and was the Training Officer of the Section of Oncology of the Department of Medicine at the Veteran's Memorial Medical Center, and is also the Chair of the Institutional Review Board.

She is an active consultant physician specializing in Medical Oncology at the University of Perpetual Help DALTA Medical Center and Veteran's Memorial Medical Center.

She also has a long list of clinical trials she has participated in and has presented scientific papers both locally and internationally.

Curriculum Vitae



SHAHEENA DAWOOD, MD

Dr. Shaheenah Dawood is a consultant medical oncologist and associate professor of clinical oncology in the United Arab Emirates. She trained in medical oncology at McGill University Hospital in Canada and subspecialized in breast cancer management at MD Anderson Cancer Center, USA. A multiple scholar in training and ASCO merit awardee, our speaker has served as an editorial fellow at the New England Journal of Medicine and has an MPH from the Harvard School of Public Health.

She has over 100 papers to her credit including 52 peer review original articles, 32 review articles and 12 book chapters. She also serves as a reviewer for multiple journals including the Journal of Clinical Oncology. She currently leads the oncology clinical trials program at Mediclinic City Hospital Dubai and serves as the president of the Excellence in Oncology Summit held annually in Dubai. She is co-president of the Asia Pacific Breast Cancer Summit (ABCS) and Asia Pacific Gastrointestinal Cancer Summit (APGCS) and has launched the international BRCA forum and MENA Immune-Oncology Summit.



ELLIE MAY B. VILLEGAS, MD, FPCP, FPSMO

Dr. Ellie May Villegas is a past president of the Philippine Society of Medical Oncology and chair of the Philippine Society Board of Medical Oncology. Presently, she is co-chair of the Perpetual Succour Hospital Institutional Ethics and Review Board, and is Section Head of the Hema-Onco Unit at the Perpetual Succour Hospital, Cebu Cancer Institute.

Our distinguished speaker is also an Associate Professor at the Cebu Doctors' University Hospital and is an active member of the medical staff of various hospitals including Chong Hua Hospital, Visayas Community Medical Center, and Cebu Velez General Hospital. She is a principal investigator and co-investigator in over 21 major clinical trials, both ongoing and in-progress.

Abstract

The Role of Lenvatinib in the Management of HCC: The Present and Future **Dr. Choo Su Pin**

Targeted therapy remains to be one of the proven modalities in the management of liver cancer amidst the advent of immune-oncology therapies. Lenvatinib is an oral multikinase inhibitor that is approved as monotherapy in first line unresectable HCC and we aim to showcase Lenvatinib and the benefits patients with uHCC can receive by sharing recent scientific survival data, including up and coming combination studies that could help cancer doctors in shaping the future of HCC treatment and patient management.

How to Use Eribulin in Clinics: Maximizing Survival Outcomes **Dr. See Hui Ti**

Metastatic Breast Cancer women who are heavily pre-treated are all deserving of therapies that will allow them to experience life at full potential. Eribulin mesilate is a non-taxane microtubule dynamics inhibitor with a mode of action unique among other chemotherapeutic agents and has shown to be beneficial for patients with advanced or metastatic breast cancer. We aim to highlight Eribulin's advantage by sharing scientific data and actual patient experiences reflecting its utilization in the clinics proving its significant overall survival benefits.

Role of Biosimilars in Value-based Medicine in Oncology: Experience with Biosimilar Trastuzumab **Prof. Dr. Cornelius F. Waller**

Cancer care is associated with high costs and value-based medicine offers a balance of health care provision and budget with patient access and value while utilizing evidence-based medicine to define high-value diagnostics and treatments. Value-based care aims to improve the quality of care while containing costs. As the costs of biologics are high, biosimilars offer the potential of greater choice and value as well as increased patient access to these treatments which can lead to better patient outcomes.

Abstract

Since 2004, the European Medicines Agency (EMA) has introduced a dedicated route for the approval of biosimilars and has issued scientific guidelines to help developers conform to the strict regulatory requirements for approving biosimilars in the European Union through a centralized procedure. Several biosimilars in oncology are already in the market following the strict guidelines of the EMA and the Food and Drug Administration in the US. These include growth factors and monoclonal antibodies such as rituximab and trastuzumab. Preclinical and clinical trials have demonstrated the efficacy and safety of these approved biosimilars. The introduction of biosimilars has led to price reductions, enhanced competition and increased patient access to high quality biopharmaceuticals. Education of physicians and other health care providers with regards to biosimilar development, regulatory approval and concepts such as extrapolation and interchangeability is crucial in order to optimize the use of biosimilars. Trials on a biosimilar trastuzumab will be presented as an illustrative example.

Improving Outcomes of EGFR Mutated NSCLC Beyond FLAURA

Dr. Gerardo H. Cornelio

Osimertinib is the standard of care for 1st line treatment of EGFR mutated advanced NSCLC with proven PFS, OS, CNS activity, and safety based on the FLAURA study. Emerging data supports the use of Osimertinib as adjuvant therapy for EGFR mutant early-stage NSCLC after surgery based on the ADAURA study with 79% reduction in the risk of disease recurrence or death and clinically meaningful improvement in CNS DFS. Understanding acquired resistance to Osimertinib is key to treatment strategies after progression and is now the subject of ongoing clinical trials.

Abstract

The Role of Biosimilar Filgrastim in Chemotherapy Induced Neutropenia **Dr. Sreedhar Sagi**

Biosimilars are biologic medicines that have been proven, through a regulatory process, to be highly similar to a reference product. Several biosimilars of Filgrastim are now in clinical use in Europe and elsewhere. Acceptance of biosimilar filgrastim is reflected in EORTC guidelines, recommending biosimilar filgrastim as well as the reference product to prevent chemotherapy-induced neutropenia.

Quality standards in manufacturing apply equally to all biologics including biosimilars. Sandoz biosimilar Filgrastim, through Phase I to Phase IV studies, was evaluated for clinical efficacy and safety in reference to the innovator product.

Studies demonstrate that biosimilar and the reference Filgrastim are similar with no clinically meaningful differences regarding efficacy and safety in prevention of severe neutropenia. Biosimilar Filgrastim could represent an important alternative to the reference product, potentially benefiting public health by increasing access to Filgrastim treatment.

Help Keep What Matters Intact. Preventing Bone Complication through Denosumab **Dr. Annielyn Beryl A. Ong-Cornel**

Metastatic Bone disease affects our patients' quality of life. It presents our patients with burdens which will range from physical to emotional to financial. The Burden and impact of Bone complications must be recognized early, since early intervention provides the patients with longer time to pain, longer time to radiation, decreased pathologic fractures, improved quality of lie and decreased bone related expenditures.

It is necessary to initiate a bone management program concurrently with the initiation of cancer treatment to prevent complications of bone metastasis.

Abstract

Approach to the treatment of bone metastases requires an integrated and aggressive approach. This includes early diagnosis, induction of bone modifying agents, pain control, indications for radiation and systemic treatment.

Management of bone metastases is evaluated in terms of the prevention of SREs, using parameters such as time to first SRE, skeletal morbidity rate or multiple-event analysis

Bone modifying agents like zoledronic acid and Denosumab have played central roles in the management of bone complications/skeletal related events. Several large trials have shown that Denosumab offers better results in terms of delaying time to first SRE, skeletal morbidity rate, better pain control and better quality of life.

Raising Standards in HR+/HER2-mBC with CDK4/6 Inhibitors Measuring Recent Progress

Dr. Shaheenah Dawood and Dr. Ellie May B. Villegas

Raising Standards in HR+/HER2- mBC with CDK4/6 Inhibitors: Measuring Recent Progress – Not all patients will respond in the same way to endocrine therapy. This lecture answers the important questions to consider in incorporating CDK4/6i in the management of patients with HR+ve/HER2-ve advanced breast cancer in today's setting including: 1) Do CDK4/6i improve overall survival when used in the endocrine sensitive setting? 2) Do CDK4/6i improve overall survival when used in the endocrine resistant setting? and 3) When is the best time to use CDK4/6i? The local experience with CDK4/6 inhibitors will also be presented.

The Inductees

NEW ASSOCIATE MEMBERS

1. Alcantara, Michelle Joane E.
2. Ando, Mark M.
3. Aranilla, Jestoni V.
4. Berba, Carlo Miguel P.
5. Buenacosa-Nepucpuan, Emmelyn B.
6. Chua Jr, Alfred V.
7. Dantes, Ma. Angelle Lalaine D.
8. Domingo, Cristina G.
9. Gonzales, Adeline C.
10. Hernandez, Aylmer Rex B.
11. Leones, Louis Mervyn B.
12. Lim, Imee Loren C.
13. Lopez, Stephen E.
14. Mascardo-Mercado, Yancel Donna L.
15. Mendoza, Marvin Jonne L.
16. Patacsil, John Marvin T.
17. Pineda, Beverly Ann P.
18. Pizarro, Dean Marvin P.
19. Realuyo, Madonna Vida R.
20. Tan, Harold Nathan C.

The Inductees



Alcantara, Michelle Joane E.



Ando, Mark M.



Aranilla, Jestoni V.



Berba, Carlo Miguel P.



**Buenacosa-Nepucpan,
Emmelyn B.**



Chua Jr, Alfred V.



**Dantes, Ma. Angelle
Lalaine D.**



Domingo, Cristina G.

The Inductees



Gonzales, Adeline C.



Hernandez, Aylmer Rex B.



Leones, Louis Mervyn B.



Lim, Imee Loren C.



Lopez, Stephen E.



**Mascardo-Mercado, Yancel
Donna L.**



Mendoza, Marvin Jonne L.



Patacsil, John Marvin T.

The Inductees



Pineda, Beverly Ann P.



Pizarro, Dean Marvin P.



Realuyo, Madonna Vida R.



Tan, Harold Nathan C.

Organizing Committee 2021

19TH MIDYEAR CONVENTION



Josephine P. Contreras-Tolentino, MD
Overall Chair



Hiyasmin P. Acero-Alejandro, MD
Overall Co-Chair

Scientific Program Committee



Herdee Gloriane C. Luna, MD
Chair



Kenny Jun N. Demegillo, MD
Co-Chair



Arthur Jason S. Go, MD
Co-Chair

Scientific Program Committee



Ana Lea S. Lava, MD
Co-Chair



Amherstia B. Morelos, MD
Co-Chair

Invitations and Publicity Committee



Jay-Ar B. Palec, MD
Chair



Norman F. Cabaya, MD
Co-Chair

Socials Committee



Jay T Datukan, MD
Chair



Pauline Anne P. Cauton, MD
Co-Chair



**Elaine Marisse H.
Ilagan-Cargullo, MD**
Co-Chair



Louella Grace Lira-Roces, MD
Co-Chair

Virtual Events Committee



Ann Meredith U. Garcia-Trinidad, MD
Chair



Edgar Christian S. Cuaresma, MD
Co-Chair



Raji R. Shamaileh, MD
Co-Chair

Registration Committee



Francisca Rosario B. Espino-Tan, MD
Chair



Amabelle Trina B. Gerona, MD
Co-Chair



Maria Karen Luisa A. Villanueva-Timbol, MD
Co-Chair

Ways and Means Committee



Katrina P. Ferrera-Calma, MD
Chair

Publication Committee



Mary Gay B. Buliyat, MD
Chair

Virtual Booth Committee



Charles Vincent O. Uy, MD
Chair

Governing Council



Buenaventura C. Ramos, Jr., MD
President



Arnold John B. Uson, MD
Vice President

Governing Council



Honey Sarita J. Abarquez, MD
Secretary



Carlos Dy, MD
Treasurer



Grace S. Nilo, MD
Internal Auditor

Council Members



Josephine P. Contreras-Tolentino, MD



Abdiel P. Galicia, MD

Council Members



Rosario V. Pitargue, MD



Andrew A. Yacat, MD

Governing Council



Jose S. Garcia, Jr., MD
Immediate Past President

Sponsors



Sponsors



hvc

human health care



eribulin
mesilate

Halaven[®]

500 mcg/ml (1mg/2ml)
Solution for Injection (I.V.)
MITOTIC INHIBITOR

MORE THAN JUST SURVIVAL

LENVATINIB



LENVIMA[®]

4 mg and 10 mg Capsules
Protein Kinase Inhibitor

RESPONSE THAT MATTERS

Sponsors



Sponsors

SANDOZ A Novartis
Division

Sponsors



VIATRIS

Sponsors



ZP

THERAPEUTICS

making healthcare more accessible

for inquiries, please contact:

PSMO Secretariat

Unit 1418, 14th Floor, North Tower Cathedral Heights Bldg.
St. Luke's Medical Center, E. Rodriguez Ave., Quezon City

Telefax: (+632) 8721-9326, 8723-0101 loc. 5318

Email: psmo_secretariat@yahoo.com

psmosecretariat@gmail.com

Visit: www.psmo.org.ph